- Home
- ACNB vs VNDA Comparison
ACNB vs VNDA Comparison
Compare ACNB & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACNB | VNDA |
|---|---|---|
| Founded | 1857 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.6M | 425.5M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | ACNB | VNDA |
|---|---|---|
| Price | $47.89 | $8.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $49.50 | $13.63 |
| AVG Volume (30 Days) | 28.1K | ★ 3.0M |
| Earning Date | 01-22-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.34 | N/A |
| Revenue | $136,676,000.00 | ★ $212,074,000.00 |
| Revenue This Year | $41.56 | $12.01 |
| Revenue Next Year | $4.18 | $21.57 |
| P/E Ratio | $14.49 | ★ N/A |
| Revenue Growth | ★ 28.45 | 11.12 |
| 52 Week Low | $35.70 | $3.81 |
| 52 Week High | $53.41 | $9.60 |
Technical Indicators
Market Signals| Indicator | ACNB | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 68.37 |
| Support Level | $46.86 | $7.82 |
| Resistance Level | $49.11 | $9.60 |
| Average True Range (ATR) | 1.20 | 0.49 |
| MACD | -0.47 | 0.10 |
| Stochastic Oscillator | 11.14 | 64.52 |
Price Performance
Historical ComparisonAbout ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.